Posted by Michael Wonder on 27 Sep 2016
Axovant Sciences receives FDA fast track designation for intepirdine as an investigational treatment for dementia with Lewy bodies
26 September 2016 - Axovant Sciences today announced that the company has received fast track designation for its investigational new drug application for intepirdine in the treatment of dementia with Lewy bodies from the U.S. FDA.
"We are pleased that FDA has placed a high priority on the development of intepirdine as a potential treatment for dementia with Lewy bodies," stated Dr. Lawrence Friedhoff, Chief Development Officer of Axovant Sciences. "Dementia with Lewy bodies is the second-leading form of progressive dementia and affects over 1 million people in the United States and currently there are no approved treatments for the disease in either the United States or Europe. We believe the HEADWAY-DLB study of intepirdine in dementia with Lewy bodies represents an important step to address the unmet need of patients with this condition."
